跳至主要内容
临床试验/NCT04507282
NCT04507282已完成不适用

Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Bursa Postgraduate Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2020年5月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
1
主要终点
subprophylactic anticogulation level

研究概览

简要总结

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
  • agreed to participate in the study were included

排除标准

  • Patients with previous coagulopathy,
  • continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
  • glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

研究组 & 干预措施

COVID 19 positive patients

干预措施: LMWH (Drug)

结局指标

主要结局

subprophylactic anticogulation level

时间窗: 14 days

\<0.2IU/ml

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hasan ARI

Medical Doctor of Cardiology

Bursa Postgraduate Hospital

研究点 (1)

Loading locations...

相似试验